6294-54-8

Basic information

• Product Name: 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione
• Synonyms: 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione
• CAS NO: 6294-54-8
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.19
• Mol File: 6294-54-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.277g/cm³
• Refractive Index: 1.553
• CAS DataBase Reference: 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione(6294-54-8)
• EPA Substance Registry System: 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione(6294-54-8)

Safety Data

• Hazardous Substances Data: 6294-54-8(Hazardous Substances Data)

Usage

General Description

5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione is a chemical compound with the molecular formula C9H9N3O2. It is a heterocyclic compound containing both a pyridine and imidazolidine ring. This chemical compound is used in the synthesis of pharmaceuticals and can also act as a ligand in coordination chemistry. It possesses potential biological activities and has been studied for its potential medicinal uses. 5-Methyl-5-pyridin-4-yl-imidazolidine-2,4-dione is mainly used in research and development in the pharmaceutical industry.

InChI:InChI=1/C9H9N3O2/c1-9(6-2-4-10-5-3-6)7(13)11-8(14)12-9/h2-5H,1H3,(H2,11,12,13,14)

Upstream product

• 1122-54-9 methyl (4-pyridyl) ketone 
• 506-87-6 ammonium carbonate 
• 1066-33-7 ammonium bicarbonate 
• 55-22-1 pyridine-4-carboxylic acid 
• 100-48-1 pyridine-4-carbonitrile 
• 151-50-8 potassium cyanide 

Relevant articles and documents

Identification and Profiling of Hydantoins - A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-d-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.